Review of atypical antipsychotics in anxiety.
Eur Neuropsychopharmacol
; 21(6): 429-49, 2011 Jun.
Article
en En
| MEDLINE
| ID: mdl-21345655
ABSTRACT
Atypical antipsychotics are increasingly used for treatment of anxiety disorders, either in mono- or combination therapy. This is the first review reporting on the use of atypical antipsychotics in monotherapy or augmentation in patients with primary anxiety disorders or anxiety (disorders) comorbid to schizophrenia, bipolar disorder (BPD) and major depressive disorder (MDD). We included 49 open-label trials, 32 randomized, placebo-controlled trials (RCTpls) and five randomized controlled trials without placebo arm with almost 6000 patients (open-label 1710, randomized 4145). An increasing number of RCTpls show promising results in 27-71% of patients with primary or comorbid anxiety disorders who were treated with monotherapy atypical antipsychotics or augmentation therapy. However, methodological flaws of included studies may limit conclusions of this review and larger placebo-controlled trials are warranted comparing standard treatment with monotherapy and augmentation therapy of atypical antipsychotics and placebo. In addition, higher dropout rates and side effects from treatment with atypical antipsychotics may limit the use of atypical antipsychotics in patients with anxiety disorders.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Trastornos de Ansiedad
/
Antipsicóticos
/
Trastornos Mentales
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
/
Systematic_reviews
Límite:
Humans
Idioma:
En
Revista:
Eur Neuropsychopharmacol
Asunto de la revista:
PSICOFARMACOLOGIA
Año:
2011
Tipo del documento:
Article
País de afiliación:
Países Bajos